BioGaia AB Class B (GB:0GTN)
LSE:0GTN
0GTN Stock Chart & Stats
kr105.70
kr1.00(0.90%)
At close: 4:00 PM EST
kr105.70
kr1.00(0.90%)
Day’s Range― - ―
52-Week Rangekr93.60 - kr122.00
Previous CloseN/A
Volume2.49K
Average Volume (3M)6.59K
Market Cap
kr12.14B
Enterprise Valuekr11.02B
Total Cash (Recent Filing)kr801.31M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)32.3
Beta0.53
Next Earnings
May 13, 2026EPS Estimate
0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding98,497,170
10 Day Avg. Volume4,070
30 Day Avg. Volume6,588
Financial Highlights & Ratios
PEG Ratio-6.22
Price to Book (P/B)8.17
Price to Sales (P/S)6.98
P/FCF Ratio35.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.04
Revenue Forecast (FY)kr1.66B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year revenue expansion from ~0.75B to ~1.54B demonstrates durable demand for BioGaia’s probiotic products and distribution reach. Sustained top-line growth supports scale advantages, improves leverage on fixed costs, and provides a stable base to fund R&D and market expansion over the next several quarters.
High Gross MarginsPersistently high gross margins (~72–74%) signal structural pricing power and a favorable cost base for the probiotic business. This margin profile supports reinvestment in clinical documentation and marketing, cushions against input-cost volatility, and underpins long-term operating profitability and cash generation.
Very Low LeverageEssentially no net debt and a conservative balance sheet reduce financial risk and preserve strategic optionality. Low leverage lowers refinancing risk, enables opportunistic M&A or marketing investments, and provides resilience to industry cycles for at least the next several quarters.
Bears Say
Margin CompressionNet margin contraction from ~34% to ~22% despite higher sales indicates rising costs or greater investment intensity that are eroding profitability. If structural (higher SG&A, clinical spend, or price pressure), this reduces retained earnings and could limit sustainable earnings and dividend capacity over the medium term.
Weakening Free Cash FlowFree cash flow declined ~6% in 2025 and operating/free cash flow fell versus 2023–24 even as revenue rose, signaling cash conversion pressure. Persistent deterioration in cash conversion can constrain reinvestment, increase reliance on balance-sheet buffers, and pressure liquidity for growth initiatives over coming quarters.
Declining Equity BaseEquity falling from ~2.03B to ~1.31B is a notable structural trend that reduces the capital cushion. Over time a shrinking equity base can limit financial flexibility, raise scrutiny on capital allocation (dividends, buybacks), and weaken resilience to shocks or larger strategic investments.
BioGaia AB News
0GTN FAQ
What was BioGaia AB Class B’s price range in the past 12 months?
BioGaia AB Class B lowest share price was kr93.60 and its highest was kr122.00 in the past 12 months.
What is BioGaia AB Class B’s market cap?
BioGaia AB Class B’s market cap is kr12.14B.
When is BioGaia AB Class B’s upcoming earnings report date?
BioGaia AB Class B’s upcoming earnings report date is May 13, 2026 which is in 30 days.
How were BioGaia AB Class B’s earnings last quarter?
BioGaia AB Class B released its earnings results on Feb 12, 2026. The company reported kr0.98 earnings per share for the quarter, beating the consensus estimate of kr0.8 by kr0.18.
Is BioGaia AB Class B overvalued?
According to Wall Street analysts BioGaia AB Class B’s price is currently Overvalued.
Does BioGaia AB Class B pay dividends?
BioGaia AB Class B does not currently pay dividends.
What is BioGaia AB Class B’s EPS estimate?
BioGaia AB Class B’s EPS estimate is 0.78.
How many shares outstanding does BioGaia AB Class B have?
BioGaia AB Class B has 98,497,170 shares outstanding.
What happened to BioGaia AB Class B’s price movement after its last earnings report?
BioGaia AB Class B reported an EPS of kr0.98 in its last earnings report, beating expectations of kr0.8. Following the earnings report the stock price went down -5.825%.
Which hedge fund is a major shareholder of BioGaia AB Class B?
Currently, no hedge funds are holding shares in GB:0GTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioGaia AB Class B
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylorithe gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---